An iPad-based clinician programmer will give physicians a “command center” view of all Neuspera implanted devices and external wireless transmitters within their practices. The programmer’s advanced functionality allows clinicians to modify a number of treatment parameters for patients, change electrode configurations, set stimulation program specifications, and pair one or more wireless transmitters to an implant. Data visualization features display usage and other useful information to help physicians work with patients to optimize therapy.
Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will enroll 145 patients at 25 sites globally. The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat overactive bladder (OAB) for patients with urinary urgency incontinence (UUI) symptoms. The system is the first sacral neuromodulation (SNM)...
Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, Treo Ventures, joined the Board of Directors. Returning Series A and Series B investors include Action Potential Venture Capital and Windham Venture Partners. The...
Neuspera Medical Inc., a clinical stage, private, venture capital backed neuromodulation company, announced the receipt of an Investigational Device Exemption (IDE) from the FDA – enabling the company to conduct the first long-term clinical trial of its ultra-miniaturized neuromodulation platform. An MRI Conditional version of Neuspera’s wirelessly powered implant designed for use as a sacral nerve stimulator will be studied for treatment of Urinary Urge Incontinence (UUI) – a prevalent form of...
Neuspera Medical has raised a new total of $26 million in equity financing, following the closing of the second tranche of its series B round, to help fund clinical testing programs for its neuromodulation implants.
Each of the round’s original investors returned to participate, including 6 Dimensions Capital, Action Potential Venture Capital, Windham Venture Partners, Delta Capital, Purple Arch Ventures and others.
The second and final $12 million tranche was triggered after the company met development...
Customer reviews
No reviews were found for Neuspera - iPad-based Clinician Programmer. Be the first to review!